It’s far better to be alone than to be in bad company

od Duruisseaux, Michael, Cadranel, Jacques
izdano v J Thorac Dis (2019)

How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?

od Denis, Morgane, Duruisseaux, Michael, Brevet, Marie, Dumontet, Charles
izdano v Front Immunol (2020)

Pro-tumoural CXCL10/CXCR3-A autocrine loop in invasive mucinous lung adenocarcinoma

od Duruisseaux, Michaël, Rabbe, Nathalie, Antoine, Martine, Vieira, Thibault, Poulot, Virginie, Cadranel, Jacques, Wislez, Marie
izdano v ERJ Open Res (2017)

NRG1 fusion in a French cohort of invasive mucinous lung adenocarcinoma

od Duruisseaux, Michaël, McLeer‐Florin, Anne, Antoine, Martine, Alavizadeh, Sanaz, Poulot, Virginie, Lacave, Roger, Rabbe, Nathalie, Cadranel, Jacques, Wislez, Marie
izdano v Cancer Med (2016)

Factors associated with early progression of non-small-cell lung cancer treated by epidermal growth factor receptor tyrosine-kinase inhibitors

od Rozensztajn, Nathalie, Ruppert, Anne-Marie, Lavole, Armelle, Leprieur, Etienne Giroux, Duruisseaux, Michael, Vieira, Thibault, Rabbe, Nathalie, Lacave, Roger, Antoine, Martine, Cadranel, Jacques, Wislez, Marie
Izdano 2014

Investigating the Impact of Immune-Related Adverse Events, Glucocorticoid Use and Immunotherapy Interruption on Long-Term Survival Outcomes

od de la Bruyère, Charline Lafayolle, Souquet, Pierre-Jean, Dalle, Stéphane, Corbaux, Pauline, Boespflug, Amélie, Duruisseaux, Michaël, Kiakouama-Maleka, Lize, Reverdy, Thibaut, Maugeais, Madeleine, Sahin, Gulsum, Maillet, Denis, Péron, Julien
izdano v Cancers (Basel) (2021)

VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations

od Hervé, Virginie, Rabbe, Nathalie, Guilleminault, Laurent, Paul, Flora, Schlick, Laurène, Azzopardi, Nicolas, Duruisseaux, Michael, Fouquenet, Delphine, Montharu, Jérôme, Redini, Françoise, Paintaud, Gilles, Lemarié, Etienne, Cadranel, Jacques, Wislez, Marie, Heuzé-Vourc’h, Nathalie
izdano v MAbs (2014)

Does Very Poor Performance Status Systematically Preclude Single Agent Anti-PD-1 Immunotherapy? A Multicenter Study of 35 Consecutive Patients

od Gounant, Valérie, Duruisseaux, Michael, Soussi, Ghassen, Van Hulst, Sylvie, Bylicki, Olivier, Cadranel, Jacques, Wislez, Marie, Trédaniel, Jean, Spano, Jean-Philippe, Helissey, Carole, Chouaid, Christos, Molinier, Olivier, Dhalluin, Xavier, Doucet, Ludovic, Hureaux, José, Cazes, Aurélie, Zalcman, Gérard
izdano v Cancers (Basel) (2021)

Therapeutic Potential of Afatinib in NRG1 Fusion‐Driven Solid Tumors: A Case Series

od Cadranel, Jacques, Liu, Stephen V., Duruisseaux, Michaël, Branden, Eva, Goto, Yasushi, Weinberg, Benjamin A., Heining, Christoph, Schlenk, Richard F., Cheema, Parneet, Jones, Martin R., Drilon, Alexander, Trombetta, Domenico, Muscarella, Lucia Anna, Tolba, Khaled, Gounant, Valerie, Cseh, Agnieszka, Solca, Flavio, Laskin, Janessa J., Renouf, Daniel J.
izdano v Oncologist (2020)

Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study

od Duruisseaux, Michaël, Besse, Benjamin, Cadranel, Jacques, Pérol, Maurice, Mennecier, Bertrand, Bigay-Game, Laurence, Descourt, Renaud, Dansin, Eric, Audigier-Valette, Clarisse, Moreau, Lionel, Hureaux, José, Veillon, Remi, Otto, Josiane, Madroszyk-Flandin, Anne, Cortot, Alexis, Guichard, François, Boudou-Rouquette, Pascaline, Langlais, Alexandra, Missy, Pascale, Morin, Franck, Moro-Sibilot, Denis
izdano v Oncotarget (2017)

Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non–Small-Cell Lung Cancer

od Gadgeel, Shirish M., Shaw, Alice T., Govindan, Ramaswamy, Gandhi, Leena, Socinski, Mark A., Camidge, D. Ross, De Petris, Luigi, Kim, Dong-Wan, Chiappori, Alberto, Moro-Sibilot, Denis L., Duruisseaux, Michael, Crino, Lucio, De Pas, Tommaso, Dansin, Eric, Tessmer, Antje, Yang, James Chih-Hsin, Han, Ji-Youn, Bordogna, Walter, Golding, Sophie, Zeaiter, Ali, Ou, Sai-Hong Ignatius
izdano v J Clin Oncol (2016)

Pulmonary Fibrosis in Antineutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis: A Series of 49 Patients and Review of the Literature

od Comarmond, Cloé, Crestani, Bruno, Tazi, Abdellatif, Hervier, Baptiste, Adam-Marchand, Sylvain, Nunes, Hilario, Cohen-Aubart, Fleur, Wislez, Marie, Cadranel, Jacques, Housset, Bruno, Lloret-Linares, Célia, Sève, Pascal, Pagnoux, Christian, Abad, Sébastien, Camuset, Juliette, Bienvenu, Boris, Duruisseaux, Michaël, Hachulla, Eric, Arlet, Jean-Benoît, Hamidou, Mohammed, Mahr, Alfred, Resche-Rigon, Matthieu, Brun, Anne-Laure, Grenier, Philippe, Cacoub, Patrice, Saadoun, David
izdano v Medicine (Baltimore) (2014)

Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program

od Illini, Oliver, Hochmair, Maximilian Johannes, Fabikan, Hannah, Weinlinger, Christoph, Tufman, Amanda, Swalduz, Aurélie, Lamberg, Kristina, Hashemi, Sayed M. S., Huemer, Florian, Vikström, Anders, Wermke, Martin, Absenger, Gudrun, Addeo, Alfredo, Banerji, Shantanu, Calles, Antonio, Clarke, Stephen, Di Maio, Massimo, Durand, Alice, Duruisseaux, Michaël, Itchins, Malinda, Kääränien, Okko-Sakari, Krenn, Florian, Laack, Eckart, de Langen, Adrianus Johannes, Mohorcic, Katja, Pall, Georg, Passaro, Antonio, Prager, Gerald, Rittmeyer, Achim, Rothenstein, Jeffrey, Schumacher, Michael, Wöll, Ewald, Valipour, Arschang
izdano v Ther Adv Med Oncol (2021)